PHYSIOSOL IN PLASTIC CONTAINER

Physiosol In Plastic Container Adverse Events Reported to the FDA Over Time

How are Physiosol In Plastic Container adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Physiosol In Plastic Container, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Physiosol In Plastic Container is flagged as the suspect drug causing the adverse event.

Most Common Physiosol In Plastic Container Adverse Events Reported to the FDA

What are the most common Physiosol In Plastic Container adverse events reported to the FDA?

Death	139 (11.54%)
Peritonitis Bacterial	65 (5.4%)
Peritonitis	53 (4.4%)
Sepsis	38 (3.16%)
Peritoneal Dialysis Complication	25 (2.08%)
Sclerosing Encapsulating Peritoniti...	24 (1.99%)
Pyrexia	21 (1.74%)
Fungal Peritonitis	19 (1.58%)
Abdominal Pain	18 (1.5%)
Vomiting	18 (1.5%)
Peritonitis Sclerosing	17 (1.41%)
	Show More
Nausea	15 (1.25%)
Cardiac Arrest	14 (1.16%)
Catheter Site Infection	13 (1.08%)
Ileus	13 (1.08%)
Pneumonia	13 (1.08%)
Cardiac Failure	12 (1%)
Cerebrovascular Accident	12 (1%)
Ascites	11 (.91%)
General Physical Health Deteriorati...	11 (.91%)
Intestinal Obstruction	11 (.91%)
Peritoneal Cloudy Effluent	11 (.91%)
Constipation	10 (.83%)
Cardiac Disorder	9 (.75%)
Dyspnoea	9 (.75%)
Fluid Overload	9 (.75%)
Malaise	9 (.75%)
Acute Myocardial Infarction	8 (.66%)
Diarrhoea	8 (.66%)
Anuria	7 (.58%)
Multi-organ Failure	7 (.58%)
Renal Failure Chronic	7 (.58%)
Weight Decreased	7 (.58%)
Abdominal Distension	6 (.5%)
Asthenia	6 (.5%)
Cachexia	6 (.5%)
Dyspepsia	6 (.5%)
Hypertension	6 (.5%)
Hypotension	6 (.5%)
Intestinal Ischaemia	6 (.5%)
Staphylococcal Infection	6 (.5%)
Cardio-respiratory Arrest	5 (.42%)
Chills	5 (.42%)
Convulsion	5 (.42%)
Gastrointestinal Disorder	5 (.42%)
Hyperphosphataemia	5 (.42%)
Infection	5 (.42%)
Intra-abdominal Haematoma	5 (.42%)
Procedural Complication	5 (.42%)
Urinary Tract Infection	5 (.42%)
Abdominal Abscess	4 (.33%)
Abdominal Symptom	4 (.33%)
Anaemia	4 (.33%)
Dehydration	4 (.33%)
Diverticulitis	4 (.33%)
Hypokalaemia	4 (.33%)
Ischaemic Stroke	4 (.33%)
Malnutrition	4 (.33%)
Pancreatitis	4 (.33%)
Peripheral Ischaemia	4 (.33%)
Peripheral Vascular Disorder	4 (.33%)
Pleural Effusion	4 (.33%)
Pneumothorax	4 (.33%)
Post Procedural Complication	4 (.33%)
Reflux Oesophagitis	4 (.33%)
Septic Shock	4 (.33%)
Tachycardia	4 (.33%)
Therapy Cessation	4 (.33%)
Urosepsis	4 (.33%)
Abdominal Pain Upper	3 (.25%)
Abdominal Wall Infection	3 (.25%)
Abscess Intestinal	3 (.25%)
Atelectasis	3 (.25%)
Bacteraemia	3 (.25%)
Blood Pressure Increased	3 (.25%)
Body Temperature Increased	3 (.25%)
Cytomegalovirus Infection	3 (.25%)
Dementia	3 (.25%)
Depressed Level Of Consciousness	3 (.25%)
Eczema	3 (.25%)
Enterococcal Infection	3 (.25%)
Escherichia Infection	3 (.25%)
Fistula	3 (.25%)
Flank Pain	3 (.25%)
Flatulence	3 (.25%)
Gangrene	3 (.25%)
Gastrointestinal Oedema	3 (.25%)
Haematoma Infection	3 (.25%)
Haemodynamic Instability	3 (.25%)
Haemoglobin Decreased	3 (.25%)
Haemorrhagic Anaemia	3 (.25%)
Haemorrhagic Ascites	3 (.25%)
Hernia	3 (.25%)
Hypotonia	3 (.25%)
Ill-defined Disorder	3 (.25%)
Intra-abdominal Haemorrhage	3 (.25%)
Ischaemia	3 (.25%)
Oedema	3 (.25%)
Pancreatitis Acute	3 (.25%)
Peritoneal Disorder	3 (.25%)
Peritoneal Fluid Analysis Abnormal	3 (.25%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Physiosol In Plastic Container, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Physiosol In Plastic Container is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Physiosol In Plastic Container

What are the most common Physiosol In Plastic Container adverse events reported to the FDA?

Fatal Outcomes	146 (12.13%)
Infections - Pathogen Unspecified	136 (11.3%)
Peritoneal And Retroperitoneal Cond...	126 (10.47%)
Bacterial Infectious	88 (7.31%)
Gastrointestinal Signs	74 (6.15%)
Procedural And Device Related Injur...	40 (3.32%)
Gastrointestinal Stenosis And Obstr...	28 (2.33%)
Cardiac Arrhythmias	27 (2.24%)
Central Nervous System Vascular	23 (1.91%)
Fungal Infectious	23 (1.91%)
Body Temperature Conditions	21 (1.74%)
	Show More
Electrolyte And Fluid Balance Condi...	21 (1.74%)
Gastrointestinal Motility And Defec...	21 (1.74%)
Respiratory	19 (1.58%)
Renal Disorders	17 (1.41%)
Gastrointestinal Conditions	14 (1.16%)
Heart Failures	14 (1.16%)
Physical Examination Topics	13 (1.08%)
Appetite And General Nutritional	12 (1%)
Arteriosclerosis, Stenosis, Vascula...	11 (.91%)
Coronary Artery	11 (.91%)
Epidermal And Dermal Conditions	11 (.91%)
Cardiac Disorder Signs	10 (.83%)
Musculoskeletal And Connective Tiss...	10 (.83%)
Exocrine Pancreas Conditions	9 (.75%)
Pleural	9 (.75%)
Decreased And Nonspecific Blood Pre...	8 (.66%)
Gastrointestinal Inflammatory Condi...	8 (.66%)
Hematology Investigations	8 (.66%)
Lower Respiratory Tract Disorders	8 (.66%)
Seizures	8 (.66%)
Anemias Nonhemolytic And Marrow Dep...	7 (.58%)
Bone, Calcium, Magnesium And Phosph...	7 (.58%)
Gastrointestinal Hemorrhages	7 (.58%)
Injuries	7 (.58%)
Neurological	7 (.58%)
Vascular	7 (.58%)
Cardiac And Vascular Investigations	6 (.5%)
Gastrointestinal Vascular Condition...	6 (.5%)
Vascular Hypertensive	6 (.5%)
Bone And Joint Injuries	4 (.33%)
Embolism And Thrombosis	4 (.33%)
Gastrointestinal	4 (.33%)
Hematological And Lymphoid Tissue T...	4 (.33%)
Mental Impairment	4 (.33%)
Therapeutic Procedures And Supporti...	4 (.33%)
Viral Infectious	4 (.33%)
Diabetic Complications	3 (.25%)
Muscle	3 (.25%)
Neuromuscular	3 (.25%)
Pericardial	3 (.25%)
Product Quality Issues	3 (.25%)
White Blood Cell	3 (.25%)
Abdominal Hernias And Other Abdomin...	2 (.17%)
Bladder And Bladder Neck Disorders	2 (.17%)
Breast Neoplasms Malignant And Unsp...	2 (.17%)
Encephalopathies	2 (.17%)
Gastrointestinal Therapeutic Proced...	2 (.17%)
Hepatic And Hepatobiliary	2 (.17%)
Lymphomas	2 (.17%)
Myocardial	2 (.17%)
Pulmonary Vascular	2 (.17%)
Respiratory And Mediastinal Neoplas...	2 (.17%)
Retina, Choroid And Vitreous Hemorr...	2 (.17%)
Thyroid Gland	2 (.17%)
Tissue	2 (.17%)
Vascular Hemorrhagic	2 (.17%)
Water, Electrolyte And Mineral	2 (.17%)
Administration Site Reactions	1 (.08%)
Allergic Conditions	1 (.08%)
Anal And Rectal Conditions	1 (.08%)
Ancillary Infectious Topics	1 (.08%)
Aneurysms And Artery Dissections	1 (.08%)
Bone And Joint Therapeutic Procedur...	1 (.08%)
Bone Disorders	1 (.08%)
Deliria	1 (.08%)
Disturbances In Thinking	1 (.08%)
Gallbladder	1 (.08%)
Gastrointestinal Ulceration And Per...	1 (.08%)
Glucose Metabolism Disorders	1 (.08%)
Headaches	1 (.08%)
Hematopoietic Neoplasms	1 (.08%)
Hemolyses And Related Conditions	1 (.08%)
Hepatobiliary	1 (.08%)
Hepatobiliary Neoplasms Malignant A...	1 (.08%)
Injuries By Physical Agents	1 (.08%)
Iron And Trace Metal Metabolism	1 (.08%)
Joint	1 (.08%)
Leukemias	1 (.08%)
Lifestyle Issues	1 (.08%)
Metabolic, Nutritional And Blood Ga...	1 (.08%)
Metabolism	1 (.08%)
Microbiology And Serology	1 (.08%)
Peripheral Neuropathies	1 (.08%)
Plasma Cell Neoplasms	1 (.08%)
Platelet	1 (.08%)
Psychiatric And Behavioural Symptom...	1 (.08%)
Sleep Disturbances	1 (.08%)
Therapeutic And Nontherapeutic Effe...	1 (.08%)
Thoracic Disorders	1 (.08%)
Vision	1 (.08%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Physiosol In Plastic Container, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Physiosol In Plastic Container is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.